Objective:Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer(NSCLC),but no direct Mcl-1 inhibitor is currently available for clinical use.Thus,novel therapeutic strategi...Objective:Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer(NSCLC),but no direct Mcl-1 inhibitor is currently available for clinical use.Thus,novel therapeutic strategies are urgently needed to target Mcl-1 and sensitize the anti-NSCLC activity of Bcl-2 inhibitors.Methods:Cell proliferation was measured using sulforhodamine B and colony formation assays,and apoptosis was detected with Annexin V-FITC staining.Gene expression was manipulated using siRNAs and plasmids.Real-time PCR and Western blot were used to measure mRNA and protein levels.Immunoprecipitation and immunofluorescence were used to analyze co-localization o f dual specificity tyrosine-phosphorylation-regulated kinase 1A(DYRK1A)and Mcl-1.Results:Suppression of DYRK1A resulted in reduced Mcl-1 expression in NSCLC cells,whereas overexpression of DYRK1A significantly increased Mcl-1 expression.Suppression of DYRK1A did not alter Mcl-1 mRNA levels,but did result in an accelerated degradation o f Mcl-1 protein in NSCLC cells.Furthermore,DYRK1A mediated proteasome-dependent degradation o f Mcl-1 in NSCLC cells,and DYRK1A co-localized with Mcl-1 in NSCLC cells and was co-expressed with Mcl-1 in tumor samples from lung cancer patients,suggesting that Mcl-1 may be a novel DYRK1A substrate.We showed that combined therapy with harmine and Bcl-2 antagonists significantly inhibited cell proliferation and induced apoptosis in NSCLC cell lines as well as primary NSCLC cells.Conclusions:Mcl-1 is a novel DYRK1A substrate,and the role of DYRK1A in promoting Mcl-1 stability makes it an attractive target for decreasing Bcl-2 inhibitor resistance.展开更多
Dual-specificity tyrosine-phosphorylation-regulated kinase 1A(DYRK1A)is the most promising target for diabetes treatment by promotingβ-cell proliferation.The desmethylbellidifolin(DMB)as a DYRK1A inhibitor could faci...Dual-specificity tyrosine-phosphorylation-regulated kinase 1A(DYRK1A)is the most promising target for diabetes treatment by promotingβ-cell proliferation.The desmethylbellidifolin(DMB)as a DYRK1A inhibitor could facilitateβ-cell proliferation in vivo and in vitro.However,DMB has the problem of weak binding affinity to DYRK1A,which means that continuous high concentration administration of DMB is effective for the diabetes.In order to solve this problem,we designed and synthesized a series of DMBbased proteolysis targeting chimeras(PROTACs)by taking advantage of the property of PROTAC that induce protein degradation in a cycle-catalytic manner.MDM2-based PROTAC X1-4P-MDM2 was identified as the most active PROTAC molecule.Mechanism research showed that X1-4P-MDM2 formed a ternary complex with DYRK1A and murine double minute 2(MDM2),and induced the degradation of DYRK1A through the ubiquitin-proteasome system pathway.At a dose much lower than that of DMB,X1-4PMDM2 still significantly enhancedβ-cell proliferation by inhibiting transforming growth factor beta(TGF-β)and promoting the mitogen-activated protein kinases/extracellular signal-regulated kinase(MAPK/ERK)signaling pathway,which may provide a new strategy for the application of DMB in diabetes.展开更多
Dual specificity tyrosine phosphorylation regulated kinase 1 A(DYRK1 A) is an evolutionarily conserved protein kinase belonging to the CMGC kinase family, which is closely related to Down syndrome(DS)and Alzheimer’s ...Dual specificity tyrosine phosphorylation regulated kinase 1 A(DYRK1 A) is an evolutionarily conserved protein kinase belonging to the CMGC kinase family, which is closely related to Down syndrome(DS)and Alzheimer’s disease(AD). In recent years, not only the treatment of diabetes, but also the treatment of cancer gradually focuses on targeting DYRK1 A. Therefore, a series of DYRK1 A inhibitors have been developed to treat relevant diseases and clarify their treatment mechanism furtherly. DYRK1 A inhibitors are mainly divided into natural products and synthetic compounds. Among them, harmine is an excellent DYRK1 A inhibitor. Therefore, the synthetic DYRK1 A inhibitors are mainly based on harmine, which greatly enriches the structure and quantity of DYRK1 A inhibitors. The interaction between the inhibitors and the DYRK1 A protein has a guiding significance in predicting the activity of the inhibitors, and plays an irreplaceable role in the design of the compounds. This paper mainly reviews DYRK1 A inhibitors found in recent years and their structure-activity relationship, looking forward to providing a theoretical basis for the development of DYRK1 A inhibitors.展开更多
目的探讨双特异性酪氨酸磷酸化调节激酶1b(DYRK1b)在宫颈病变组织和癌细胞中的表达情况及其作用.方法选取宫颈癌患者127例为研究组,同期确诊为慢性宫颈炎患者32例为对照组,收集上述患者石蜡组织标本,免疫组化SP法检测DYRK1b蛋白表达情况...目的探讨双特异性酪氨酸磷酸化调节激酶1b(DYRK1b)在宫颈病变组织和癌细胞中的表达情况及其作用.方法选取宫颈癌患者127例为研究组,同期确诊为慢性宫颈炎患者32例为对照组,收集上述患者石蜡组织标本,免疫组化SP法检测DYRK1b蛋白表达情况.依据宫颈癌细胞系He La 229和Si Ha细胞将标本分为实验组(加DYRK1b抑制剂Az191)、对照组(不加Az191),Western blod法检测细胞中DYRK1蛋白表达情况,MTT法检测细胞增殖情况,流式细胞仪检测细胞凋亡情况.结果子宫颈鳞癌阳性表达率明显高于慢性宫颈炎、低级别鳞状上皮内病变、高级别鳞状上皮内病变,差异均具有统计学意义(P<0.01);高级别鳞状上皮内病变明显高于慢性宫颈炎、低级别鳞状上皮内病变,差异具有统计学意义(P<0.05).在He La 229和Si Ha细胞中,DYRK1b蛋白表达量随Az191剂量增加而减少,且均明显低于对照组,差异具有统计学意义(P<0.01).研究组He La 229和Si Ha细胞抑制率随Az191浓度增加而提升,均明显高于对照组,差异具有统计学意义(P<0.05).10μmol/L的Az191作用后,研究组He La 229和Si Ha细胞凋亡率明显高于对照组,差异具有统计学意义(P<0.05).结论宫颈病变过程中DYRK1b蛋白表达水平逐渐提升,宫颈癌组织和细胞中均呈高表达;下调DYRK1b蛋白表达后可抑制宫颈癌细胞增殖,促进凋亡.展开更多
基金the National Natural Science Foundation of China(Grant Nos.81702887,81272473)the Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province(Grant No.2020E10021)+6 种基金the Key Medical Disciplines of Zhejiang Province(Grant No.2018-2-3)the Hangzhou Major Science and Technology Project(Grant No.20172016A01)the Zhejiang Provincial Foundation of Natural Science(Grant No.LY19H310004)the Scientific and Technological Developing Scheme of Hangzhou City(Grant No.20191203B49)the Science Research Foundation of Zhejiang Health Bureau(Grant No.2020RC026)the High-level Talents Coming Back from Abroad Innovation,the Entrepreneurship Program in Hangzhouand the Teachers Research Fund of Zhejiang University City College(Grant No.J-19006).
文摘Objective:Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer(NSCLC),but no direct Mcl-1 inhibitor is currently available for clinical use.Thus,novel therapeutic strategies are urgently needed to target Mcl-1 and sensitize the anti-NSCLC activity of Bcl-2 inhibitors.Methods:Cell proliferation was measured using sulforhodamine B and colony formation assays,and apoptosis was detected with Annexin V-FITC staining.Gene expression was manipulated using siRNAs and plasmids.Real-time PCR and Western blot were used to measure mRNA and protein levels.Immunoprecipitation and immunofluorescence were used to analyze co-localization o f dual specificity tyrosine-phosphorylation-regulated kinase 1A(DYRK1A)and Mcl-1.Results:Suppression of DYRK1A resulted in reduced Mcl-1 expression in NSCLC cells,whereas overexpression of DYRK1A significantly increased Mcl-1 expression.Suppression of DYRK1A did not alter Mcl-1 mRNA levels,but did result in an accelerated degradation o f Mcl-1 protein in NSCLC cells.Furthermore,DYRK1A mediated proteasome-dependent degradation o f Mcl-1 in NSCLC cells,and DYRK1A co-localized with Mcl-1 in NSCLC cells and was co-expressed with Mcl-1 in tumor samples from lung cancer patients,suggesting that Mcl-1 may be a novel DYRK1A substrate.We showed that combined therapy with harmine and Bcl-2 antagonists significantly inhibited cell proliferation and induced apoptosis in NSCLC cell lines as well as primary NSCLC cells.Conclusions:Mcl-1 is a novel DYRK1A substrate,and the role of DYRK1A in promoting Mcl-1 stability makes it an attractive target for decreasing Bcl-2 inhibitor resistance.
基金the National Natural Science Foundation of China(NSFC,No.82141216)Chunhui Program-Cooperative Research Project of the Ministry of Education+5 种基金Liaoning Province Natural Science Foundation(No.2022-MS-241)Shenyang Young and Middle-aged Innovative Talents Support Program(No.RC210446)“Select the best candidates to lead key research projects”of Fujian University of Traditional Chinese Medicine(No.XJB2022008)Foundation of Fujian University of Traditional Chinese Medicine(No.X2023001-Talent)the support from National-Local Joint Engineering Research Center for Molecular Biotechnology of Fujian&Taiwan TCMat Fujian University of Traditional Chinese Medicine。
文摘Dual-specificity tyrosine-phosphorylation-regulated kinase 1A(DYRK1A)is the most promising target for diabetes treatment by promotingβ-cell proliferation.The desmethylbellidifolin(DMB)as a DYRK1A inhibitor could facilitateβ-cell proliferation in vivo and in vitro.However,DMB has the problem of weak binding affinity to DYRK1A,which means that continuous high concentration administration of DMB is effective for the diabetes.In order to solve this problem,we designed and synthesized a series of DMBbased proteolysis targeting chimeras(PROTACs)by taking advantage of the property of PROTAC that induce protein degradation in a cycle-catalytic manner.MDM2-based PROTAC X1-4P-MDM2 was identified as the most active PROTAC molecule.Mechanism research showed that X1-4P-MDM2 formed a ternary complex with DYRK1A and murine double minute 2(MDM2),and induced the degradation of DYRK1A through the ubiquitin-proteasome system pathway.At a dose much lower than that of DMB,X1-4PMDM2 still significantly enhancedβ-cell proliferation by inhibiting transforming growth factor beta(TGF-β)and promoting the mitogen-activated protein kinases/extracellular signal-regulated kinase(MAPK/ERK)signaling pathway,which may provide a new strategy for the application of DMB in diabetes.
基金funded by the National Natural Science Foundation of China (No. 82073311)National Key Research and Development Program of China (No. 2020YFC2005500)+2 种基金Key Research and Development Program of Science and Technology Department of Sichuan Province (No. 2019YFS0514)Clinical Research and Transformation Fund of Sichuan Provincial People’s Hospital (No. 2021LZ03)the State Administration of Traditional Chinese Medicine (No.JDZX2015210)。
文摘Dual specificity tyrosine phosphorylation regulated kinase 1 A(DYRK1 A) is an evolutionarily conserved protein kinase belonging to the CMGC kinase family, which is closely related to Down syndrome(DS)and Alzheimer’s disease(AD). In recent years, not only the treatment of diabetes, but also the treatment of cancer gradually focuses on targeting DYRK1 A. Therefore, a series of DYRK1 A inhibitors have been developed to treat relevant diseases and clarify their treatment mechanism furtherly. DYRK1 A inhibitors are mainly divided into natural products and synthetic compounds. Among them, harmine is an excellent DYRK1 A inhibitor. Therefore, the synthetic DYRK1 A inhibitors are mainly based on harmine, which greatly enriches the structure and quantity of DYRK1 A inhibitors. The interaction between the inhibitors and the DYRK1 A protein has a guiding significance in predicting the activity of the inhibitors, and plays an irreplaceable role in the design of the compounds. This paper mainly reviews DYRK1 A inhibitors found in recent years and their structure-activity relationship, looking forward to providing a theoretical basis for the development of DYRK1 A inhibitors.
文摘目的探讨双特异性酪氨酸磷酸化调节激酶1b(DYRK1b)在宫颈病变组织和癌细胞中的表达情况及其作用.方法选取宫颈癌患者127例为研究组,同期确诊为慢性宫颈炎患者32例为对照组,收集上述患者石蜡组织标本,免疫组化SP法检测DYRK1b蛋白表达情况.依据宫颈癌细胞系He La 229和Si Ha细胞将标本分为实验组(加DYRK1b抑制剂Az191)、对照组(不加Az191),Western blod法检测细胞中DYRK1蛋白表达情况,MTT法检测细胞增殖情况,流式细胞仪检测细胞凋亡情况.结果子宫颈鳞癌阳性表达率明显高于慢性宫颈炎、低级别鳞状上皮内病变、高级别鳞状上皮内病变,差异均具有统计学意义(P<0.01);高级别鳞状上皮内病变明显高于慢性宫颈炎、低级别鳞状上皮内病变,差异具有统计学意义(P<0.05).在He La 229和Si Ha细胞中,DYRK1b蛋白表达量随Az191剂量增加而减少,且均明显低于对照组,差异具有统计学意义(P<0.01).研究组He La 229和Si Ha细胞抑制率随Az191浓度增加而提升,均明显高于对照组,差异具有统计学意义(P<0.05).10μmol/L的Az191作用后,研究组He La 229和Si Ha细胞凋亡率明显高于对照组,差异具有统计学意义(P<0.05).结论宫颈病变过程中DYRK1b蛋白表达水平逐渐提升,宫颈癌组织和细胞中均呈高表达;下调DYRK1b蛋白表达后可抑制宫颈癌细胞增殖,促进凋亡.
